Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.
about
Low dose cytarabine monotherapy for acute myeloid leukaemiaHypomethylating agents for adult patients with acute myeloid leukaemiaInterleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remissionInterleukin-2 as maintenance therapy for children and adults with acute myeloid leukaemia in first complete remissionHypomethylating agents for adult patients with acute myeloid leukaemiaLow dose cytarabine monotherapy for acute myeloid leukaemiaChromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AMLSirtuins in hematological aging and malignancyGene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.Overexpression of MN1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and Bim inductionOutcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades.Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial.Phase I study of oral clofarabine consolidation in adults aged 60 and older with acute myeloid leukemia.Leukemia associated antigens: their dual role as biomarkers and immunotherapeutic targets for acute myeloid leukemiaInteractions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis.Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemiaEffect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy.Challenges in treating older patients with acute myeloid leukemia.Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease.Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendationsIntronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway.Association between baseline body mass index and overall survival among patients over age 60 with acute myeloid leukemiaPopulation-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysisBAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.Deferasirox and vitamin D improves overall survival in elderly patients with acute myeloid leukemia after demethylating agents failure.Expression and prognostic impact of lncRNAs in acute myeloid leukemia.Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemiaLow expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia.A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapyHeritable polymorphism predisposes to high BAALC expression in acute myeloid leukemiamiR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemiaSuccessful application of a direct detection slide-based sequential phenotype/genotype assay using archived bone marrow smears and paraffin embedded tissue sections.Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutationsPrognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia.Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experienceTreatment of acute myeloid leukemia in older patients.
P2860
Q24186270-2770E4CA-D1DE-4B9B-88A6-6BC624005C40Q24186284-A4090AE5-FC43-4FB9-993E-FB4213C09494Q24187927-9EBB7CC4-2497-49C0-A64B-CE2F13B8B1C3Q24202630-4B03830A-D976-4A31-96ED-DC6F8AF83936Q24234645-753FDB6C-5FED-4E23-8C6C-DCD8CADA0381Q24234680-1689BD1E-E6C2-4BE3-BDF3-10FE4CFCC3ECQ24645177-030028AB-0C06-410D-9E20-BC7DF07E9C76Q26991467-F3DE446F-99E7-4AAC-9E01-5DB5EC9062DCQ27851460-1C6130D3-BAC2-4B45-A3ED-67348824C223Q27851545-4D63FCC5-0238-42A2-9EA3-B5F8A7A8A0C4Q28482247-AE17B736-4BB9-4C76-A863-CEA5903BA362Q30620658-19031C85-946F-40E6-8475-375B4D51ADA8Q33264716-6DF489FD-9B7B-4A56-8BBA-9891BE7938CCQ33412609-1563C66B-9C33-4C9C-92DD-6999D216FA15Q33491557-BE08FA1E-B011-42BA-A6FD-23D4EFF67F16Q33840247-E2940A36-1C6C-44BF-9560-A2FE6B5042E2Q33859061-4FCD9CD8-8313-4F0A-B634-64956C98EE7EQ33943277-7514FF97-6612-4A3A-8287-51C158E1ADEDQ33968372-7443AECB-549A-4DEC-A02E-95C8BC89B149Q33985549-4934DFB6-30B1-4E6C-B59D-AC8F70378324Q34022803-77412343-2E43-488E-8C4D-594587717B5FQ34031134-B1E44EA3-34E2-45FC-A3D6-9603C7D9F68BQ34193684-AEB65453-2518-4085-B389-CB5C0EB9F606Q34428550-C58767C7-3F16-4E8C-8CBA-9687D4EA08DEQ34428556-58295BBE-571D-4C36-9925-35D80882960EQ34541748-68B7D0B7-9EF5-4042-A3B0-155B400A845FQ34804866-89C40E70-B9FC-460D-A10E-69942FB2B8CFQ34831106-45052F1A-F05F-433E-8159-4796B59B0267Q35651754-5135481C-949C-4199-A16D-02C431C3B237Q35794120-54CAE8F0-C3B2-404E-8BC5-53B537D74C7BQ35794439-9CA1B709-E5CD-412E-963F-64148219E77CQ35922032-10EC595E-3321-49A8-A069-3CED914565BEQ36100455-A1F03D95-5E16-4B4A-8881-7FBFBEB293BCQ36103451-35C0EB4E-54C7-4772-AC82-6D4026BA6554Q36219674-48A2A895-EA99-4BF8-B37F-AD873465C883Q36400942-BD80C716-DC9D-438A-8ED9-29B86AE925ABQ36457184-CB19BFD9-BB31-4BAE-B7A9-57703D8E8D4FQ36498399-FD268B6B-AE06-44BE-B224-4DF9A16B8076Q36713551-B4800598-DED0-4EE1-8442-A54FCB849AD6Q36752023-D146FDC6-82B2-4B44-8329-827874D61489
P2860
Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Cytogenetics and age are major ...... s from AMLSG trial AML HD98-B.
@ast
Cytogenetics and age are major ...... s from AMLSG trial AML HD98-B.
@en
Cytogenetics and age are major ...... s from AMLSG trial AML HD98-B.
@nl
type
label
Cytogenetics and age are major ...... s from AMLSG trial AML HD98-B.
@ast
Cytogenetics and age are major ...... s from AMLSG trial AML HD98-B.
@en
Cytogenetics and age are major ...... s from AMLSG trial AML HD98-B.
@nl
prefLabel
Cytogenetics and age are major ...... s from AMLSG trial AML HD98-B.
@ast
Cytogenetics and age are major ...... s from AMLSG trial AML HD98-B.
@en
Cytogenetics and age are major ...... s from AMLSG trial AML HD98-B.
@nl
P2093
P1433
P1476
Cytogenetics and age are major ...... s from AMLSG trial AML HD98-B.
@en
P2093
Axel Benner
German-Austrian AML Study Group
Martina Morhardt
Richard F Schlenk
Sabine Kayser
Stefan Fröhling
P304
P356
10.1182/BLOOD-2006-04-014324
P407
P577
2006-07-13T00:00:00Z